NEW YORK, March 3 - Sequitur said today that it has expanded an existing agreement with Bristol-Myers Squibb to include work with RNAi.
Sequitur said it is now entering the fourth year of the existing collaboration, under which it has been performing biological screening assays for target validation. Under the expanded agreement, the company will also provide BMS with RNAi -- a form of double-stranded RNA that causes sequence-specific inhibition of target mRNAs -- for use in target validation studies.
In January 2001, Sequitur agreed to provide BMS with antisense compounds for target validation.
Sequitur's other clients include Incyte Genomics, GlaxoSmithKline, Pfizer, Genentech, Procter and Gamble, Harvard University, the Mayo Clinic, Scripps, Roche, Schering-Plough, and Wyeth.